Top

Supportive Care in Cancer

Published in:

01-08-2012 | Original Article

Efficacy and safety of aprepitant in the prevention of chemotherapy-induced nausea and vomiting: a pooled analysis

Authors: Yan Jin, Xiaomin Wu, Yanmeng Guan, Dongying Gu, Yue Shen, Zhi Xu, Xiaowei Wei, Jinfei Chen

Published in: Supportive Care in Cancer | Issue 8/2012

Abstract

Purpose

A number of studies have reported that aprepitant has been used to prevent chemotherapy-induced nausea and vomiting. In this study, we aimed to analyze the efficacy and safety of aprepitant, which can provide evidence for aprepitant administration.

Materials and methods

Fifteen trials involving patients who received moderately or highly emetogenic chemotherapy were included in this pooled analysis. Antiemetic drugs in these studies included aprepitant, dexamethasone, and 5-HT3 receptor antagonists.

Results

A total of 4,798 cases were investigated in these clinical trials. Compared with placebo or the standard antiemetic therapy, the cumulative incidence of emesis was significantly reduced in the patients treated with aprepitant-based (125 mg/80 mg) therapy on the first day [relative risk (RR) = 1.13, 95% confidence interval (CI) 1.10–1.16], from 2 to 5 days (RR = 1.35, 95% CI 1.22–1.48) and in the overall 5 days (RR = 1.30, 95% CI 1.22–1.39). In terms of drug safety, there was no significant difference between aprepitant-based regimens and non-aprepitant regimens.

Conclusion

Results from the analysis suggest that aprepitant with 5-HT3 receptor antagonists and dexamethasone is highly effective in preventing nausea and vomiting in the days after administration of moderately or highly emetogenic chemotherapy (MEC or HEC) agents.

Osoba D et al (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 5(4):307–313PubMedCrossRef

Watcha MF (2002) Postoperative nausea and emesis. Anesthesiol Clin North America 20(3):709–722PubMedCrossRef

Wender RH (2009) Do current antiemetic practices result in positive patient outcomes? Results of a new study. Am J Health Syst Pharm 66(1 Suppl 1):S3–S10PubMedCrossRef

Jordan K et al (2007) A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer 15(9):1023–1033PubMedCrossRef

Campos D et al (2001) Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 19(6):1759–1767PubMed

Madsen JL, Fuglsang S (2008) A randomized, placebo-controlled, crossover, double-blind trial of the NK1 receptor antagonist aprepitant on gastrointestinal motor function in healthy humans. Aliment Pharmacol Ther 27(7):609–615PubMedCrossRef

Sanchez RI et al (2004) Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos 32(11):1287–1292PubMedCrossRef

Reddy GK, Gralla RJ, Hesketh PJ (2006) Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis. Support Canc Ther 3(3):140–142CrossRef

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188PubMedCrossRef

10.

Gore L et al (2009) Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer 52(2):242–247PubMedCrossRef

11.

Yeo W et al (2009) A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy. Breast Cancer Res Treat 113(3):529–535PubMedCrossRef

12.

Schmoll HJ et al (2006) Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17(6):1000–1006PubMedCrossRef

13.

Warr DG et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23(12):2822–2830PubMedCrossRef

14.

Hesketh PJ et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol 21(22):4112–4119PubMedCrossRef

15.

de Wit R et al (2003) Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 21(22):4105–4111PubMedCrossRef

16.

Poli-Bigelli S et al (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97(12):3090–3098PubMedCrossRef

17.

Chawla SP et al (2003) Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 97(9):2290–2300PubMedCrossRef

18.

Rapoport BL et al (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18(4):423–431PubMedCrossRef

19.

Herrington JD, Jaskiewicz AD, Song J (2008) Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 112(9):2080–2087PubMedCrossRef

20.

Galy G et al (2009) Aprepitant for the prevention of cisplatine induced nausea and vomiting: an observational study. Bull Cancer 96(2):141–145PubMed

21.

Takahashi T et al (2010) Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. Cancer Sci 101(11):2455–2461PubMedCrossRef

22.

Roila F et al (2009) Randomized, double-blind, dose-ranging trial of the oral neurokinin-1 receptor antagonist casopitant mesylate for the prevention of cisplatin-induced nausea and vomiting. Ann Oncol 20(11):1867–1873PubMedCrossRef

23.

Navari RM et al (1999) Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist L-754,030 Antiemetic Trials Group. N Engl J Med 340(3):190–195PubMedCrossRef

24.

Rojas C et al (2010) The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther 335(2):362–368PubMedCrossRef

25.

Grunberg SM et al (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100(10):2261–2268PubMedCrossRef

26.

Eisenberg P et al (2004) Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann Oncol 15(2):330–337PubMedCrossRef

27.

Choi MR, Jiles C, Seibel NL (2010) Aprepitant use in children, adolescents, and young adults for the control of chemotherapy-induced nausea and vomiting (CINV). J Pediatr Hematol Oncol 32(7):e268–e271PubMedCrossRef

28.

Navari RM (2003) Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting–two new agents. J Support Oncol 1(2):89–103PubMed

29.

Grunberg SM et al (2009) Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer 17(5):589–594PubMedCrossRef

30.

Stoch SA et al (2011) Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant. Cancer Chemother Pharmacol 67:1313–1321PubMedCrossRef

Title: Efficacy and safety of aprepitant in the prevention of chemotherapy-induced nausea and vomiting: a pooled analysis
Authors: Yan Jin
Xiaomin Wu
Yanmeng Guan
Dongying Gu
Yue Shen
Zhi Xu
Xiaowei Wei
Jinfei Chen
Publication date: 01-08-2012
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 8/2012
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-011-1280-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2012

Illness appraisal, religious coping, and psychological responses in men with advanced cancer

Partner-assisted emotional disclosure for patients with GI cancer: 8-week follow-up and processes associated with change

Topical silver sulfadiazine for the prevention of acute dermatitis during irradiation for breast cancer

Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer

Trends in anemia management in lung and colon cancer patients in the US Department of Veterans Affairs, 2002–2008

Nutritional status, acute phase response and depression in metastatic lung cancer patients: correlations and association prognosis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer